Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob A Rappaport

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Anesthesia and Analgesia|April 19, 2008
FDA response to droperidol black box warning editorialsBob A Rappaport
The New England Journal of Medicine|June 18, 2010
The reality of drug shortages--the case of the injectable agent propofolValerie Jensen, Bob A Rappaport
Anesthesia and Analgesia|February 22, 2007
The Food and Drug Administration perspective: use of an investigational drug in a medical emergencyLex W Schultheis, Bob A Rappaport
Anesthesia and Analgesia|October 25, 2011
SmartTots: a multidisciplinary effort to determine anesthetic safety in young childrenJames G Ramsay, Bob A Rappaport
Anesthesia and Analgesia|December 8, 2025
SmartTots and the Power of Scientific Public-Private Partnerships With the US Food and Drug AdministrationThomas Cooper, Bob A Rappaport, Beverley A Orser
Anesthesiology|February 4, 2010
ACTION on the prevention of chronic pain after surgery: public-private partnerships, the future of analgesic drug developmentBob A Rappaport, Igor Cerny, Wendy R Sanhai
Anesthesia and Analgesia|February 22, 2007
Use of anesthetic agents in neonates and young childrenR Daniel Mellon, Arthur F Simone, Bob A Rappaport
CNS Neuroscience & Therapeutics|April 27, 2012
Reanalysis of methamphetamine dependence treatment trialCelia Winchell, Bob A Rappaport, Rigoberto Roca, et al.
Lancet (London, England)|August 23, 2011
Injectable extended-release naltrexone for opioid dependenceDouglas C Throckmorton, Robert Temple, Bob A Rappaport, et al.
The New England Journal of Medicine|February 26, 2015
Anesthetic neurotoxicity--clinical implications of animal modelsBob A Rappaport, Santhanam Suresh, Sharon Hertz, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Anesthesia and Analgesia|April 19, 2008
FDA response to droperidol black box warning editorialsBob A Rappaport
The New England Journal of Medicine|June 18, 2010
The reality of drug shortages--the case of the injectable agent propofolValerie Jensen, Bob A Rappaport
Anesthesia and Analgesia|February 22, 2007
The Food and Drug Administration perspective: use of an investigational drug in a medical emergencyLex W Schultheis, Bob A Rappaport
Anesthesia and Analgesia|October 25, 2011
SmartTots: a multidisciplinary effort to determine anesthetic safety in young childrenJames G Ramsay, Bob A Rappaport
Anesthesia and Analgesia|December 8, 2025
SmartTots and the Power of Scientific Public-Private Partnerships With the US Food and Drug AdministrationThomas Cooper, Bob A Rappaport, Beverley A Orser
Anesthesiology|February 4, 2010
ACTION on the prevention of chronic pain after surgery: public-private partnerships, the future of analgesic drug developmentBob A Rappaport, Igor Cerny, Wendy R Sanhai
Anesthesia and Analgesia|February 22, 2007
Use of anesthetic agents in neonates and young childrenR Daniel Mellon, Arthur F Simone, Bob A Rappaport
CNS Neuroscience & Therapeutics|April 27, 2012
Reanalysis of methamphetamine dependence treatment trialCelia Winchell, Bob A Rappaport, Rigoberto Roca, et al.
Lancet (London, England)|August 23, 2011
Injectable extended-release naltrexone for opioid dependenceDouglas C Throckmorton, Robert Temple, Bob A Rappaport, et al.
The New England Journal of Medicine|February 26, 2015
Anesthetic neurotoxicity--clinical implications of animal modelsBob A Rappaport, Santhanam Suresh, Sharon Hertz, et al.
Pageof 6